Skip to content

Study · Observational study · n = 142 · 2026

11 results

Efficacy and safety of oral semaglutide as add-on therapy in poorly controlled type 2 diabetes on background SGLT2 inhibitors: a real-world, multi-center, retrospective, observational study (RYS2).

Malighetti ME, Vescini F, Carpentieri M, Altomari A, Turchi F, DA Porto A, Dauriz M

Minerva endocrinology27 Nov 2025

PMID41307513 (opens in a new tab)DOI10.23736/s2724-6507.25.04376-3 (opens in a new tab)PepBankPUB-41307513
Publisher pagePubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In adults with poorly controlled type 2 diabetes on SGLT2 inhibitors, adding oral semaglutide significantly improved HbA1c.

    In plain wordsIn adults with type 2 diabetes already on SGLT2 inhibitors, adding oral semaglutide improved HbA1c.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c change
    Study

    n = 142

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · oral · 6.8±2.6 monthsAs given in this study (human).

    Source sentences

    Summary
    both glycosylated hemoglobin (HbA1c) and fasting plasma glucose levels significantly improved
    1 context sentence
    Summary · context
    In this observational, single-arm, retrospective study, data collected from 142 T2DM patients (66% males, 68% older than 60 years, 85% overweight/obese) treated with oral semaglutide in combination with SGLT2i were analyzed.
  2. 02HumanObservational studyEfficacy outcome

    In adults with poorly controlled type 2 diabetes on SGLT2 inhibitors, adding oral semaglutide significantly improved fasting plasma glucose.

    In plain wordsIn adults with type 2 diabetes already on SGLT2 inhibitors, adding oral semaglutide improved fasting blood glucose.

    Peptide
    Semaglutide
    Outcome
    DecreaseFasting plasma glucose change
    Study

    n = 142

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · oral · 6.8±2.6 monthsAs given in this study (human).

    Source sentences

    Summary
    both glycosylated hemoglobin (HbA1c) and fasting plasma glucose levels significantly improved
    1 context sentence
    Summary · context
    In this observational, single-arm, retrospective study, data collected from 142 T2DM patients (66% males, 68% older than 60 years, 85% overweight/obese) treated with oral semaglutide in combination with SGLT2i were analyzed.
  3. 03HumanObservational studyEfficacy outcome

    In adults with poorly controlled type 2 diabetes on SGLT2 inhibitors, 39.6% reached HbA1c of 7% or lower after adding oral semaglutide.

    In plain wordsIn adults with type 2 diabetes on SGLT2 inhibitors, 39.6% reached HbA1c of 7% or lower after adding oral semaglutide.

    Peptide
    Semaglutide
    Outcome
    Not applicablePatients achieving HbA1c 7% or lower
    Study

    n = 142

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · oral · 6.8±2.6 monthsAs given in this study (human).

    Measurements

    Patients achieving HbA1c ≤7%
    39.6%
    oral semaglutide add-on

    Source sentences

    Summary
    39.6% of patients achieved HbA1cDCCT ≤7%
    1 context sentence
    Summary · context
    In this observational, single-arm, retrospective study, data collected from 142 T2DM patients (66% males, 68% older than 60 years, 85% overweight/obese) treated with oral semaglutide in combination with SGLT2i were analyzed.
  4. 04HumanObservational studyEfficacy outcome

    In adults with poorly controlled type 2 diabetes on SGLT2 inhibitors, 18.8% had both an HbA1c decrease of 1% or more and a weight loss of 5% or more.

    In plain wordsIn adults with type 2 diabetes on SGLT2 inhibitors, 18.8% had an HbA1c drop of 1% or more and weight loss of 5% or more.

    Peptide
    Semaglutide
    Outcome
    Not applicablePatients with HbA1c decrease of 1% or more and weight loss of 5% or more
    Study

    n = 142

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · oral · 6.8±2.6 monthsAs given in this study (human).

    Measurements

    Patients with HbA1c decrease ≥1% and weight loss ≥5%
    18.8%
    oral semaglutide add-on

    Source sentences

    Summary
    18.8% experienced both a decrease of HbA1c ≥1% and a weight loss ≥5%.
    1 context sentence
    Summary · context
    In this observational, single-arm, retrospective study, data collected from 142 T2DM patients (66% males, 68% older than 60 years, 85% overweight/obese) treated with oral semaglutide in combination with SGLT2i were analyzed.
  5. 05HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes on SGLT2 inhibitors, body weight was significantly reduced after adding oral semaglutide.

    In plain wordsIn adults with type 2 diabetes already on SGLT2 inhibitors, body weight fell after adding oral semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight change
    Study

    n = 142

    Comparator
    Baseline
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · oral · 6.8±2.6 monthsAs given in this study (human).

    Source sentences

    Summary
    In addition, body weight, body mass index, waist circumference, triglycerides, and total cholesterol levels were significantly reduced.
    1 context sentence
    Summary · context
    In this observational, single-arm, retrospective study, data collected from 142 T2DM patients (66% males, 68% older than 60 years, 85% overweight/obese) treated with oral semaglutide in combination with SGLT2i were analyzed.
  6. 06HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes on SGLT2 inhibitors, body mass index was significantly reduced after adding oral semaglutide.

    In plain wordsIn adults with type 2 diabetes already on SGLT2 inhibitors, body mass index fell after adding oral semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody mass index change
    Study

    n = 142

    Comparator
    Baseline
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · oral · 6.8±2.6 monthsAs given in this study (human).

    Source sentences

    Summary
    In addition, body weight, body mass index, waist circumference, triglycerides, and total cholesterol levels were significantly reduced.
    1 context sentence
    Summary · context
    In this observational, single-arm, retrospective study, data collected from 142 T2DM patients (66% males, 68% older than 60 years, 85% overweight/obese) treated with oral semaglutide in combination with SGLT2i were analyzed.
  7. 07HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes on SGLT2 inhibitors, waist circumference was significantly reduced after adding oral semaglutide.

    In plain wordsIn adults with type 2 diabetes already on SGLT2 inhibitors, waist size fell after adding oral semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseWaist circumference change
    Study

    n = 142

    Comparator
    Baseline
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · oral · 6.8±2.6 monthsAs given in this study (human).

    Source sentences

    Summary
    In addition, body weight, body mass index, waist circumference, triglycerides, and total cholesterol levels were significantly reduced.
    1 context sentence
    Summary · context
    In this observational, single-arm, retrospective study, data collected from 142 T2DM patients (66% males, 68% older than 60 years, 85% overweight/obese) treated with oral semaglutide in combination with SGLT2i were analyzed.
  8. 08HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes on SGLT2 inhibitors, triglycerides were significantly reduced after adding oral semaglutide.

    In plain wordsIn adults with type 2 diabetes already on SGLT2 inhibitors, triglycerides fell after adding oral semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseTriglycerides change
    Study

    n = 142

    Comparator
    Baseline
    Outcome group
    Lipids · Cardiovascular
    Studied dose
    Dose not stated · oral · 6.8±2.6 monthsAs given in this study (human).

    Source sentences

    Summary
    In addition, body weight, body mass index, waist circumference, triglycerides, and total cholesterol levels were significantly reduced.
    1 context sentence
    Summary · context
    In this observational, single-arm, retrospective study, data collected from 142 T2DM patients (66% males, 68% older than 60 years, 85% overweight/obese) treated with oral semaglutide in combination with SGLT2i were analyzed.
  9. 09HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes on SGLT2 inhibitors, total cholesterol was significantly reduced after adding oral semaglutide.

    In plain wordsIn adults with type 2 diabetes already on SGLT2 inhibitors, total cholesterol fell after adding oral semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseTotal cholesterol change
    Study

    n = 142

    Comparator
    Baseline
    Outcome group
    Lipids · Cardiovascular
    Studied dose
    Dose not stated · oral · 6.8±2.6 monthsAs given in this study (human).

    Source sentences

    Summary
    In addition, body weight, body mass index, waist circumference, triglycerides, and total cholesterol levels were significantly reduced.
    1 context sentence
    Summary · context
    In this observational, single-arm, retrospective study, data collected from 142 T2DM patients (66% males, 68% older than 60 years, 85% overweight/obese) treated with oral semaglutide in combination with SGLT2i were analyzed.
  10. 10HumanObservational studySafety outcome

    In adults with type 2 diabetes on SGLT2 inhibitors, 94.7% of reported adverse events with oral semaglutide were non-serious gastrointestinal symptoms.

    In plain wordsIn adults with type 2 diabetes on SGLT2 inhibitors, most side effects of oral semaglutide were mild stomach and bowel symptoms.

    Peptide
    Semaglutide
    Outcome
    Not applicableNon-serious gastrointestinal adverse events
    Study

    n = 142

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated · oral · 6.8±2.6 monthsAs given in this study (human).

    Measurements

    Adverse events that were non-serious gastrointestinal symptoms
    94.7%
    reported adverse events

    Source sentences

    Summary
    94.7% of reported adverse events were non-serious gastrointestinal symptoms and 1 patient experienced hypoglycemia.
    1 context sentence
    Summary · context
    In this observational, single-arm, retrospective study, data collected from 142 T2DM patients (66% males, 68% older than 60 years, 85% overweight/obese) treated with oral semaglutide in combination with SGLT2i were analyzed.
  11. 11HumanObservational studySafety outcome

    In adults with type 2 diabetes on SGLT2 inhibitors, 1 patient experienced hypoglycemia with oral semaglutide.

    In plain wordsIn adults with type 2 diabetes on SGLT2 inhibitors, one patient had low blood sugar on oral semaglutide.

    Peptide
    Semaglutide
    Outcome
    Not applicableHypoglycemia
    Study

    n = 142

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated · oral · 6.8±2.6 monthsAs given in this study (human).

    Measurements

    Patients with hypoglycemia
    1 patient
    oral semaglutide add-on

    Source sentences

    Summary
    1 patient experienced hypoglycemia.
    1 context sentence
    Summary · context
    In this observational, single-arm, retrospective study, data collected from 142 T2DM patients (66% males, 68% older than 60 years, 85% overweight/obese) treated with oral semaglutide in combination with SGLT2i were analyzed.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.